Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.02
BIOS's Cash-to-Debt is ranked lower than
92% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. BIOS: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
BIOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.47 Max: 21.72
Current: 0.02
0
21.72
Equity-to-Asset -0.05
BIOS's Equity-to-Asset is ranked lower than
94% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 0.46 vs. BIOS: -0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
BIOS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.38 Max: 0.66
Current: -0.05
-0.15
0.66
Interest Coverage 0.38
BIOS's Interest Coverage is ranked lower than
96% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.01 vs. BIOS: 0.38 )
Ranked among companies with meaningful Interest Coverage only.
BIOS' s Interest Coverage Range Over the Past 10 Years
Min: 0.19  Med: 0.63 Max: 8.06
Current: 0.38
0.19
8.06
Piotroski F-Score: 4
Altman Z-Score: 0.28
Beneish M-Score: -1.97
WACC vs ROIC
8.02%
3.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 0.78
BIOS's Operating Margin % is ranked lower than
77% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 6.53 vs. BIOS: 0.78 )
Ranked among companies with meaningful Operating Margin % only.
BIOS' s Operating Margin % Range Over the Past 10 Years
Min: -7.33  Med: 0.76 Max: 4.61
Current: 0.78
-7.33
4.61
Net Margin % -4.44
BIOS's Net Margin % is ranked lower than
82% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 4.07 vs. BIOS: -4.44 )
Ranked among companies with meaningful Net Margin % only.
BIOS' s Net Margin % Range Over the Past 10 Years
Min: -30.51  Med: -4.86 Max: 10.9
Current: -4.44
-30.51
10.9
ROA % -7.46
BIOS's ROA % is ranked lower than
86% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 3.61 vs. BIOS: -7.46 )
Ranked among companies with meaningful ROA % only.
BIOS' s ROA % Range Over the Past 10 Years
Min: -44.23  Med: -8.06 Max: 20.26
Current: -7.46
-44.23
20.26
ROC (Joel Greenblatt) % 8.73
BIOS's ROC (Joel Greenblatt) % is ranked lower than
67% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 15.77 vs. BIOS: 8.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -76.36  Med: 4.07 Max: 17.14
Current: 8.73
-76.36
17.14
3-Year Revenue Growth Rate -2.60
BIOS's 3-Year Revenue Growth Rate is ranked lower than
80% of the 182 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. BIOS: -2.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35  Med: 5.1 Max: 15.9
Current: -2.6
-35
15.9
3-Year EPS without NRI Growth Rate -25.40
BIOS's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 136 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. BIOS: -25.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.7  Med: -13.8 Max: 502.8
Current: -25.4
-82.7
502.8
GuruFocus has detected 5 Warning Signs with BioScrip Inc $BIOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIOS's 10-Y Financials

Financials (Next Earnings Date: 2017-06-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BIOS Guru Trades in Q1 2016

Diamond Hill Capital 3,568,829 sh (+16.80%)
Pioneer Investments 280,320 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 839,352 sh (-2.95%)
» More
Q2 2016

BIOS Guru Trades in Q2 2016

Paul Tudor Jones 247,500 sh (New)
Diamond Hill Capital 5,317,224 sh (+48.99%)
Mario Gabelli 904,402 sh (+7.75%)
Pioneer Investments 280,320 sh (unchged)
» More
Q3 2016

BIOS Guru Trades in Q3 2016

Pioneer Investments 280,320 sh (unchged)
Paul Tudor Jones Sold Out
Diamond Hill Capital 5,306,619 sh (-0.20%)
Mario Gabelli 875,102 sh (-3.24%)
» More
Q4 2016

BIOS Guru Trades in Q4 2016

Mario Gabelli 1,157,601 sh (+32.28%)
Pioneer Investments 280,320 sh (unchged)
Diamond Hill Capital 5,305,400 sh (-0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:NYSE:QHC, NYSE:CCM, NYSE:AAC, AMEX:HLTH, OTCPK:MIHI, OTCPK:CATS, NAS:ADUS, OTCPK:AMEH, NAS:JYNT, OTCPK:BRRZF, OTCPK:FCHS, NYSE:ADPT, OTCPK:CCEL, AMEX:AMS, OTCPK:BNKL, OTCPK:CVHIF, OTCPK:BICX, AMEX:SSY, OTCPK:PFHO, OTCPK:WNDM » details
Traded in other countries:MM6.Germany,
BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusion business; Express Scripts Holding Company through its subsidiary Accredo Health Group; and various regional and local providers of alternate site healthcare services such as hospitals, local home health agencies, and other local providers. In Home Health Services, the Company competes with Gentiva Health Services, Inc., Almost Family, Inc., Amedisys, Inc., LHC Group, Inc., among others. In PBM and Discount Card Services, the competitors include Express Scripts, Inc., Catamaran Corp., and CVS/Caremark Corp.

Ratios

vs
industry
vs
history
PS Ratio 0.17
BIOS's PS Ratio is ranked higher than
96% of the 270 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. BIOS: 0.17 )
Ranked among companies with meaningful PS Ratio only.
BIOS' s PS Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.22 Max: 2.49
Current: 0.17
0.04
2.49
EV-to-EBIT 89.29
BIOS's EV-to-EBIT is ranked lower than
97% of the 290 Companies
in the Global Medical Care industry.

( Industry Median: 19.26 vs. BIOS: 89.29 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -233  Med: 2.15 Max: 9138.1
Current: 89.29
-233
9138.1
EV-to-EBITDA 22.69
BIOS's EV-to-EBITDA is ranked lower than
86% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 14.06 vs. BIOS: 22.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -785.6  Med: 13.4 Max: 121
Current: 22.69
-785.6
121
Current Ratio 1.35
BIOS's Current Ratio is ranked higher than
53% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. BIOS: 1.35 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.3 Max: 2.17
Current: 1.35
0.86
2.17
Quick Ratio 1.07
BIOS's Quick Ratio is ranked lower than
56% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. BIOS: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.1 Max: 1.86
Current: 1.07
0.82
1.86
Days Inventory 18.97
BIOS's Days Inventory is ranked lower than
51% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 18.72 vs. BIOS: 18.97 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s Days Inventory Range Over the Past 10 Years
Min: 11.42  Med: 20.93 Max: 80.5
Current: 18.97
11.42
80.5
Days Sales Outstanding 43.62
BIOS's Days Sales Outstanding is ranked higher than
51% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 44.02 vs. BIOS: 43.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.18  Med: 47.85 Max: 178.08
Current: 43.62
36.18
178.08
Days Payable 32.22
BIOS's Days Payable is ranked lower than
61% of the 143 Companies
in the Global Medical Care industry.

( Industry Median: 40.41 vs. BIOS: 32.22 )
Ranked among companies with meaningful Days Payable only.
BIOS' s Days Payable Range Over the Past 10 Years
Min: 19.73  Med: 32.58 Max: 109.18
Current: 32.22
19.73
109.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.00
BIOS's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 129 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BIOS: -20.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20  Med: -8 Max: -0.5
Current: -20
-20
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.72
BIOS's Price-to-Median-PS-Value is ranked higher than
82% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 1.09 vs. BIOS: 0.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.11 Max: 4.62
Current: 0.72
0.23
4.62
Earnings Yield (Greenblatt) % 1.11
BIOS's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 332 Companies
in the Global Medical Care industry.

( Industry Median: 4.31 vs. BIOS: 1.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 3.2 Max: 47.3
Current: 1.11
0.7
47.3
Forward Rate of Return (Yacktman) % -8.43
BIOS's Forward Rate of Return (Yacktman) % is ranked lower than
83% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 10.14 vs. BIOS: -8.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIOS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -86.4  Med: -1.9 Max: 5.9
Current: -8.43
-86.4
5.9

More Statistics

Revenue (TTM) (Mil) $935.6
EPS (TTM) $ -0.55
Beta0.55
Short Percentage of Float24.44%
52-Week Range $0.98 - 3.43
Shares Outstanding (Mil)120.98

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 947 995 1,044
EPS ($) -0.33 -0.20 -0.04
EPS without NRI ($) -0.33 -0.20 -0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for BIOS

Headlines

Articles On GuruFocus.com
5-year lows: Elizabeth Arden Inc, Systemax Inc, BioScrip Inc, and Thompson Creek Metals Co Inc. May 26 2015 
5-year lows: Resource Capital Corp, Dynex Capital Inc, BioScrip Inc, and Kemet Corp. May 10 2015 
Two Gurus Hold Stakes in Embattled BioScrip Apr 07 2015 
A Look at Mario Gabelli's Latest Stake Increases Apr 01 2015 
Mario Gabelli Ups Stake in BioScript, But Value of Stock Declines Mar 18 2015 
A Look at Mario Gabelli's New Added Positions Feb 04 2015 
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014 
Soros and Gabelli Top Guru Real Time Picks of the Week Aug 08 2014 
Gurus' Real Time Stock Picks of the Week May 09 2014 
Morning Coffee: Real-Time Picks May 07 2014 

More From Other Websites
BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook Mar 28 2017
ETFs with exposure to BioScrip, Inc. : March 27, 2017 Mar 27 2017
9:03 am Bioscrip reaffirms FY17 adj. EBITDA; expects improved profitability following termination of... Mar 27 2017
BIOSCRIP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 27 2017
BioScrip Announces Meeting with Investors Mar 27 2017
BioScrip, Inc. :BIOS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Mar 16 2017
BioScrip, Inc. :BIOS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
BIOSCRIP, INC. Financials Mar 11 2017
Biocon Chairman Says Stock Price Warranted on Pipeline Mar 08 2017
BIOSCRIP, INC. Files SEC form 10-K, Annual Report Mar 07 2017
Company News for March 06, 2017 Mar 06 2017
Biotech's Rally in 2017 Gaining Steam After President Trump's Speech: Today's Reports on BioScrip... Mar 06 2017
BioScrip (BIOS): Q4 Loss Narrower than Expected, Sales Top Mar 06 2017
Edited Transcript of BIOS earnings conference call or presentation 3-Mar-17 2:00pm GMT Mar 03 2017
BioScrip Inc Earnings Call scheduled for 9:00 am ET today Mar 03 2017
BIOSCRIP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Mar 03 2017
BioScrip reports 4Q loss Mar 03 2017
BioScrip reports 4Q loss Mar 03 2017
BioScrip Reports Fourth Quarter and Full-Year 2016 Financial Results Mar 03 2017
Q4 2016 BioScrip Inc Earnings Release - Before Market Open Mar 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)